{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T04:34:10Z","timestamp":1769834050318,"version":"3.49.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019886","name":"Legend Biotech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019886","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.clml.2022.09.001","type":"journal-article","created":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T03:59:23Z","timestamp":1663646363000},"page":"22-27","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Recent Advances in the Use of Chimeric Antigen Receptor\u2013Expressing T-Cell Therapies for Treatment of Multiple Myeloma"],"prefix":"10.1016","volume":"23","author":[{"given":"Thomas","family":"Martin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn C.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lida","family":"Pacaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepu","family":"Madduri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sundar","family":"Jagannath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.clml.2022.09.001_bib0001","doi-asserted-by":"crossref","first-page":"5858","DOI":"10.1182\/bloodadvances.2020003391","article-title":"C(h)AR-ting a new course in incurable lymphomas: CAR T cells for mantle cell and follicular lymphomas","volume":"4","author":"Jacobson","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.clml.2022.09.001_bib0002","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"issue":"5.5","key":"10.1016\/j.clml.2022.09.001_bib0003","doi-asserted-by":"crossref","first-page":"622","DOI":"10.6004\/jnccn.2021.5017","article-title":"Update on CAR T-cell therapies for relapsed\/refractory B-cell lymphomas","volume":"19","author":"Schuster","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"26","key":"10.1016\/j.clml.2022.09.001_bib0004","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clml.2022.09.001_bib0005","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.clml.2022.09.001_bib0006","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"10254","key":"10.1016\/j.clml.2022.09.001_bib0007","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.clml.2022.09.001_bib0008","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.clml.2019.10.002","article-title":"Treatment journeys of patients with newly diagnosed multiple myeloma (NDMM): results from the connect MM registry","volume":"20","author":"Jagannath","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"10.1016\/j.clml.2022.09.001_bib0009","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/S1470-2045(20)30756-7","article-title":"Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.clml.2022.09.001_bib0010","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.clml.2022.09.001_bib0011","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.09.001_bib0012","unstructured":"Anderson LD, Jr., Shah N, Jagannath S, et\u00a0al. Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma: updated results from KarMMa. Slides presented at: 18th International Myeloma Workshop; September 8-11, 2021; Vienna, Austria. Available at: https:\/\/www.myelomasociety.org\/wp-content\/uploads\/2021\/09\/anderson-1.pdf."},{"issue":"10297","key":"10.1016\/j.clml.2022.09.001_bib0013","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2022.09.001_bib0014","unstructured":"CARVYKTI (ciltacabtagene autoleucel) [prescribing information]: Horsham, PA: Janssen Biotech; Somerset, NJ: Legend Biotech; 2022."},{"key":"10.1016\/j.clml.2022.09.001_bib0015","series-title":"Patients with Relapsed\/Refractory Multiple Myeloma. Presented at the 63rd American Society of Hematology Annual Meeting and Exposition","article-title":"Updated Results from CARTITUDE-1: Phase 1b\/2 Study of Ciltacabtagene Autoleucel, a B-cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy","author":"Martin","year":"2021"},{"key":"10.1016\/j.clml.2022.09.001_bib0016","first-page":"1","article-title":"Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor\u00a0+\u00a0dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma","author":"Rodriguez-Otero","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.clml.2022.09.001_bib0017","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-021-00507-2","article-title":"KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma","volume":"11","author":"Jagannath","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2022.09.001_bib0018","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/jha2.312","article-title":"Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE-1 versus physician\u2019s choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patientswith relapsed or refractory multiple myeloma","volume":"3","author":"Martin","year":"2022","journal-title":"eJHaem"},{"issue":"5","key":"10.1016\/j.clml.2022.09.001_bib0019","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.clml.2021.10.013","article-title":"Comparison of cilta-cel, an anti-BCMA CAR-T cell therapy, versus conventional treatment in patients with relapsed\/refractory multiple myeloma","volume":"22","author":"Costa","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.clml.2022.09.001_bib0020","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s40261-021-01100-y","article-title":"Comparative efficacy of ciltacabtagene autoleucel in CARTITUDE-1 vs physician\u2019s choice of therapy in the long-term follow-up of POLLUX, CASTOR, and EQUULEUS clinical trials for the treatment of patients with relapsed or refractory multiple myeloma","volume":"42","author":"Weisel","year":"2022","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.clml.2022.09.001_bib0021","series-title":"Slides presented at: 63rd American Society of Hematology Annual Meeting and Exposition; December 11-14, 2021; Virtual and Atlanta, GA.","article-title":"Ciltacabtagene autoleucel for triple-class exposed multiple myeloma: adjusted comparison of CARTITUDE-1 outcomes versus real world clinical practice observed from the LocoMMotion prospective study","author":"Mateos","year":"2021"},{"issue":"5","key":"10.1016\/j.clml.2022.09.001_bib0022","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1158\/2643-3230.BCD-21-0084","article-title":"Scalable Manufacturing of CAR T cells for Cancer Immunotherapy","volume":"2","author":"Abou-El-Enein","year":"2021","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.clml.2022.09.001_bib0023","first-page":"1","article-title":"Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma","author":"Martin","year":"2021","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"10.1016\/j.clml.2022.09.001_bib0024","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jgo.2020.08.004","article-title":"Characterizing inclusion and exclusion criteria in clinical trials for chimeric antigen receptor (CAR) T-cell therapy among adults with hematologic malignancies","volume":"12","author":"Jaggers","year":"2021","journal-title":"J Geriatr Oncol"},{"issue":"2","key":"10.1016\/j.clml.2022.09.001_bib0025","first-page":"13","article-title":"Associated toxicities: assessment and management related to CAR T-cell therapy","volume":"23","author":"Anderson","year":"2019","journal-title":"Clin J Oncol Nurs"},{"key":"10.1016\/j.clml.2022.09.001_bib0026","series-title":"ABECMA (idecabtagene vicleucel) [prescribing information]. Summit, NJ: Celgene; 2021","year":"2021"},{"issue":"12","key":"10.1016\/j.clml.2022.09.001_bib0027","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1038\/s41591-021-01564-7","article-title":"Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy","volume":"27","author":"Van Oekelen","year":"2021","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.clml.2022.09.001_bib0028","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","article-title":"Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies","volume":"12","author":"Cohen","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2022.09.001_bib0029","article-title":"Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma","author":"Choi","year":"2021","journal-title":"Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.clml.2022.09.001_bib0030","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41409-020-01023-w","article-title":"Chimeric antigen receptor T cell therapy in multiple myeloma: promise and challenges","volume":"56","author":"Dhakal","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.clml.2022.09.001_bib0031","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13045-021-01109-y","article-title":"Emerging therapies for relapsed\/refractory multiple myeloma: CAR-T and beyond","volume":"14","author":"Su","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"23","key":"10.1016\/j.clml.2022.09.001_bib0032","doi-asserted-by":"crossref","first-page":"6384","DOI":"10.1158\/1078-0432.CCR-21-2031","article-title":"Risk factors associated with durable progression-free survival in patients with relapsed or refractory multiple myeloma treated with Anti-BCMA CAR T-cell therapy","volume":"27","author":"Zhang","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.clml.2022.09.001_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2021.11.016","article-title":"Absolute lymphocyte count prior to lymphodepletion impacts outcomes in multiple myeloma patients treated with chimeric antigen receptor T cells","volume":"28","author":"Liu","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.clml.2022.09.001_bib0034","article-title":"Real-world evidence of axicabtagene ciloleucel for the treatment of large B cell lymphoma in the United States","author":"Jacobson","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.clml.2022.09.001_bib0035","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.3389\/fimmu.2020.01965","article-title":"Use of cell and genome modification technologies to generate improved \u201coff-the-shelf\u201d CAR T and CAR NK cells","volume":"11","author":"Morgan","year":"2020","journal-title":"Front Immunol"},{"issue":"13 Suppl","key":"10.1016\/j.clml.2022.09.001_bib0036","first-page":"S253","article-title":"Improving outcomes and mitigating costs associated with CAR T-cell therapy","volume":"27","author":"Borgert","year":"2021","journal-title":"Am J Manag Care"},{"issue":"13 Suppl","key":"10.1016\/j.clml.2022.09.001_bib0037","first-page":"S243","article-title":"Balancing the CAR T: perspectives on efficacy and safety of CAR T-cell therapy in hematologic malignancies","volume":"27","author":"Buie","year":"2021","journal-title":"Am J Manag Care"},{"issue":"2","key":"10.1016\/j.clml.2022.09.001_bib0038","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41408-020-0284-7","article-title":"Dissecting racial disparities in multiple myeloma","volume":"10","author":"Marinac","year":"2020","journal-title":"Blood Cancer J"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2022.09.001_bib0039","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1182\/blood-2021-145943","article-title":"Considerations for optimal administration of chimeric antigen receptor (CAR) T-cell therapy programs: a multi-stakeholder qualitative analysis","volume":"138","author":"Hoda","year":"2021","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2022.09.001_bib0040","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9072166","article-title":"Bispecific antibodies: a new era of treatment for multiple myeloma","volume":"9","author":"Zhou","year":"2020","journal-title":"J Clin Med"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022016846?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022016846?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:41:43Z","timestamp":1761871303000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265022016846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S2152265022016846"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2022.09.001","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent Advances in the Use of Chimeric Antigen Receptor\u2013Expressing T-Cell Therapies for Treatment of Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2022.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}